CompletedN/ADMT

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Sponsored by Merck KGaA, Darmstadt, Germany

NCT ID
NCT01601119
Target Enrollment
545 participants
Start Date
2012-01
Est. Completion
2014-07

About This Study

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Conditions Studied

Relapsing Multiple Sclerosis

Interventions

  • •Rebif
  • •Other: Disease modifying therapies (DMT)

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Relapsing Multiple Sclerosis patients aged 18 years or over.
* Naive to previous DMT therapy and not yet started treatment with a disease modifying therapy.

Exclusion Criteria:

* Participating in an MS-related clinical trial.
* Unwilling to provide electronic online consent.
* Any disability that may impair them from being able to complete the online questionnaire.
* Do not have regular access to the Internet.
* Unable to complete the baseline questionnaire before they receive their first DMT injection.

Study Locations (1)

Please contact the
Merck KGaA Communication Center For Locations, United Kingdom

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients | Huxley